Genelux reported updated interim data showing IV Olvi-Vec plus platinum chemotherapy achieved a 33% overall response rate and 67% disease control rate in heavily pretreated platinum-relapsed/refractory lung cancer patients, outperforming historical response rates, with notable tumor shrinkage and signals of a dose-response effect at higher dosing, H.C. Wainwright tells investors in a research note. Early durability signals, including progression free survival extending to 12.1 months in one case despite single-cycle dosing and no maintenance therapy, suggest potential activity in overcoming platinum resistance, with further data expected in 2026, the firm says. H.C. Wainwright has a Buy rating and $31 price target on the shares.
